More articles from From the Editor
- The bittersweet of steroid therapy
Every physician has had patients with the long-term effects of glucocorticoid therapy, including diabetes.
- A discussion of dissection
Few medical emergencies are as dramatic as an acutely rupturing aortic aneurysm. Advances in research offer potential for more alternatives to emergency surgery.
- When to stop treating the bones
Don’t let the argument about how long to treat osteoporosis with bisphosphonate drugs stand in the way of initiating therapy in patients at risk of fracture.
- Out of Morpheus’ embrace
We still lack a full understanding of the complex physiology of sleep and the effects of sleep deprivation on a number of clinical conditions, from diabetes to fi bromyalgia.
- When good drugs turn weirdly bad
Even the most specific of drugs, such as interferon, can have untoward biologic effects.
- The pain of cholesterol-lowering therapy
It seems that everyone “knows” that statins cause muscle pain, including many patients with hypercholesterolemia.
- Recognizing the unusual: The diagnostic epiphany
We have all experienced the sudden recognition of an unexpected diagnosis, such as the case of visceral angioedema due to angiotensin-converting enzyme therapy reported by Korniyenko et al in this issue of the Journal.
- Gene-based, rational drug-dosing: An evolving, complex opportunity
Pharmacogenomics promises the opportunity to match the right drug and dose to the right patient. We are not there yet, but the day is coming.
- The urge to know: What does iron have to do with infection?
Why might iron supplementation be harmful in the setting of infection?
- Hypertension: Don’t worry about the J curve—treat the patient
Concerns over being too aggressive remain theoretical. A far greater problem is that we are still not successfully treating hypertension to even a conservative target.